Immune checkpoint inhibitors and their clinical indications
| Name . | Target . | FDA-approved indication . |
|---|---|---|
| Ipilimumab | CTLA-4–blocking antibody | Melanoma |
| Nivolumab | PD-1–blocking antibody | Melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, and hepatocellular carcinoma |
| Ipilimumab + nivolumab | Melanoma, renal cell carcinoma, hepatocellular carcinoma, pleural mesothelioma, and colorectal cancer | |
| Pembrolizumab | PD-1–blocking antibody | Melanoma, non-small-cell lung cancer, small-cell lung cancer, head and neck squamous cell cancer, Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular cancer, Merkel cell carcinoma, renal cell carcinoma, and endometrial carcinoma |
| Cemiplimab | PD-1–blocking antibody | Urothelial carcinoma |
| Avelumab | PD-L1–blocking antibody | Urothelial carcinoma, Merkel cell carcinoma, and renal cell carcinoma |
| Durvalumab | PD-L1–blocking antibody | Urothelial carcinoma |
| Atezolizumab | PD-L1–blocking antibody | Urothelial carcinoma, non-small-cell lung cancer, and triple-negative breast cancer |
| Name . | Target . | FDA-approved indication . |
|---|---|---|
| Ipilimumab | CTLA-4–blocking antibody | Melanoma |
| Nivolumab | PD-1–blocking antibody | Melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, and hepatocellular carcinoma |
| Ipilimumab + nivolumab | Melanoma, renal cell carcinoma, hepatocellular carcinoma, pleural mesothelioma, and colorectal cancer | |
| Pembrolizumab | PD-1–blocking antibody | Melanoma, non-small-cell lung cancer, small-cell lung cancer, head and neck squamous cell cancer, Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular cancer, Merkel cell carcinoma, renal cell carcinoma, and endometrial carcinoma |
| Cemiplimab | PD-1–blocking antibody | Urothelial carcinoma |
| Avelumab | PD-L1–blocking antibody | Urothelial carcinoma, Merkel cell carcinoma, and renal cell carcinoma |
| Durvalumab | PD-L1–blocking antibody | Urothelial carcinoma |
| Atezolizumab | PD-L1–blocking antibody | Urothelial carcinoma, non-small-cell lung cancer, and triple-negative breast cancer |